Thanks for joining DividendStocks.com, the daily newsletter built for dividend and income investors like you. We’re thrilled to have you on board and can’t wait to help you discover the best dividend opportunities out there. Before we can start sending your daily insights, please take a quick moment to confirm your subscription: Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Why wait? Let’s get your dividend journey started! Click Here to Start Discovering Top Income-Generating Stocks See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
Today's Exclusive Story A Fresh IPO That Long-Term Investors Shouldn't IgnoreSubmitted by Jordan Chussler. Article Posted: 1/14/2026. 
Summary - While IPOs are often labeled as high-risk startups, some are worthy of more conservative investors’ attention.
- Aktis Oncology’s IPO—the first biotech IPO of 2026—resulted in a $318 million raise, with the biotech firm receiving $100 million in backing from Big Pharma giant Eli Lilly.
- The company, which now has a market cap of $3.34 billion, develops radiopharmaceuticals and is positioned for long-term success after being listed on the Nasdaq.
For speculative investors, the start of each year is a good time to revisit an initial public offering (IPO) calendar. Companies go public nearly every week, and a handful can offer considerable short-term upside potential. They also carry substantial downside risk. Even conservative investors who err on the side of caution should not overlook some recently IPO'd stocks; they may deserve a place in buy-and-hold portfolios. For the first time ever, James Altucher – one of America's top venture capitalists – is sharing how ANYONE can get a pre-IPO stake in SpaceX… with as little as $100! [[Click here now to view.]] That could be the case for one biotechnology company in the healthcare sector that just went public. Last Year’s IPO Success Stories Last year is a strong example of why IPOs shouldn't be dismissed by investors with lower risk tolerances. AI cloud computing provider CoreWeave (NASDAQ: CRWV), which went public in March 2025, is up nearly 123% since its debut. Its shares even surged roughly 359% at one point within the first 30 days on the Nasdaq, and investors who stayed on have seen strong returns. Others, such as Medline (NASDAQ: MDLN), challenge the misconception that IPOs are only for high-risk startups. The medical products and services provider, which publicly debuted in December 2025, was founded in 1966 and already boasts a market cap in excess of $55 billion. Similarly, Smithfield Foods (NASDAQ: SFD)—best known for its ubiquitous packages of bacon—waited 89 years before its IPO. Since going public in January 2025, the stock is up about 5% and pays a dividend that currently yields 4.44% ($1 per share annually), making it attractive to income investors. Aktis Oncology (NASDAQ: AKTS), a maker of radiopharmaceuticals whose shares began trading on Jan. 9, is hoping for a similar outcome in 2026 and beyond. Why Are Radiopharmaceuticals Important? Aktis Oncology specializes in radiopharmaceuticals—a subset of nuclear medicine that uses radioactive drugs for both diagnosis and treatment of diseases such as cancer, heart disease and neurological conditions. Radiopharmaceuticals combine radioactive isotopes with a targeting molecule that seeks specific cells (for example, cancer cells) to deliver localized radiation, minimizing damage to healthy tissue compared with conventional radiotherapy. According to industry consultancy Grand View Research, the global nuclear medicine market, estimated at nearly $18 billion in 2024, is forecast to reach nearly $35 billion by 2030—a compound annual growth rate of about 10.16%. Importantly for Boston-based Aktis Oncology, Grand View Research notes that North America accounts for nearly 43% of the global nuclear medicine market, with the United States as the dominant regional player. Aktis Oncology’s Clinical-Stage Profile Wall Street expects biotech IPOs to rebound in 2026 after funding changes in 2025 notably slowed healthcare-sector listings. Aktis Oncology, which debuted on the Nasdaq on Jan. 9 as the first biotech IPO of 2026, raised $318 million in its offering and now has a market cap of about $3.34 billion. According to the company’s prospectus, the executive team includes experts in drug development, approval and commercialization, with members of management having helped bring 14 currently FDA-approved products to market. At a product level, Aktis develops targeted alpha radiopharmaceuticals, a class of precision cancer drugs that use proprietary technology to target solid tumors while sparing healthy tissue. Aktis Oncology’s Eli Lilly Connection The firm is a clinical-stage, pre-revenue company, but that did not deter Eli Lilly (NYSE: LLY) from supporting its IPO. According to Reuters, Eli Lilly purchased $100 million of AKTS shares in the offering. That investment builds on a 2024 partnership in which Lilly committed $60 million in cash and an equity investment to develop tumor-targeting radiopharmaceuticals; the collaboration includes potential milestone payments exceeding $1 billion. The significance of Lilly's backing is notable. With a market cap of roughly $1.01 trillion, Eli Lilly is one of the largest pharmaceutical companies, and its net income jumped nearly 109% year-over-year from 2023 to 2024. Lilly is scheduled to report Q4 and full-year 2025 financials on Feb. 5. Between its equity stake and the $100 million purchase of AKTS shares, the maker of Zepbound now has a sizable financial interest in Aktis' success.
| 
